Dr. Pei Yang 杨锫
Chief Physician
Department of Head and Neck Radiation Oncology III, Hunan Cancer Hospital, Changsha
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Radiation therapy and comprehensive treatment for lung cancer, esophageal cancer, head and neck tumors, nasopharyngeal carcinoma, and melanoma.
Dr. Yang is Deputy Director of the Radiotherapy Department and holds a PhD from Xiangya Hospital, Central South University. Since 2002, Dr. Yang has practiced clinical oncology radiotherapy. A visiting scholar at MD Anderson Cancer Center in 2016 focusing on proton therapy and imaging omics, and a Stanford Medicine scholarship recipient in 2019, Dr. Yang participates in multidisciplinary teams for various cancers.
Professional roles
- Vice Chair and Secretary-General, Tumor Radiotherapy Committee, China Medical Education Association
- Youth Committee Member, Hyperthermia Committee, China Anti-Cancer Association
- LAMBDA Asia Regional Lead, MD Anderson Cancer Center (US)
- Member, Hunan Provincial Tumor Radiotherapy Quality Control Center
Name order: in Chinese the family name comes first (Yang Pei). Papers usually list the name as Pei Yang or Yang P.
Selected publications
32 papers on PubMed matched by name and affiliation; 8 as first or senior author since 2016. Most recent first- or senior-author papers:
- Sci Rep, 2025 (first author): The cost-effectiveness analysis of immune checkpoint inhibitors for microsatellite instability-high/mismatch repair deficient advanced colorectal cancer. PubMed 41339420
- Sci Rep, 2025 (senior author): A comparative study of quality of life and psychosocial adaptability following modified radical mastectomy and breast reconstruction. PubMed 41298903
- Front Public Health, 2024 (senior author): Cost-effectiveness analysis of Tumor Treating Fields treatment in Chinese patients with metastatic non-small cell lung cancer. PubMed 39502829
- Front Pharmacol, 2023 (senior author): Cost-effectiveness analysis of first-line tislelizumab plus chemotherapy for recurrent or metastatic nasopharyngeal cancer. PubMed 37964872
- Front Oncol, 2023 (senior author): Editorial: Application of radiomics in understanding tumor biological behaviors and treatment response. PubMed 37664068
- Int J Radiat Oncol Biol Phys, 2019 (first author): Patterns of Local-Regional Failure After Intensity Modulated Radiation Therapy or Passive Scattering Proton Therapy With Concurrent Chemotherapy for Non-Small Cell Lung Cancer. PubMed 30165127
- Oncotarget, 2017 (first author): A large-scale retrospective study of the overall survival outcome in nasopharyngeal carcinoma with hypertension in Chinese population. PubMed 29088892
- Am J Cancer Res, 2017 (first author): Analysis of the correlation among hypertension, the intake of β-blockers, and overall survival outcome in patients undergoing chemoradiotherapy with inoperable stage III non-small cell lung cancer. PubMed 28469966
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that most papers list this doctor's hospital and department.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion